170 related articles for article (PubMed ID: 14740274)
1. Equipotency of insulin glargine and regular human insulin on glucose disposal in healthy subjects following intravenous infusion.
Scholtz HE; Pretorius SG; Wessels DH; Venter C; Potgieter MA; Becker RH
Acta Diabetol; 2003 Dec; 40(4):156-62. PubMed ID: 14740274
[TBL] [Abstract][Full Text] [Related]
2. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.
Porcellati F; Rossetti P; Busciantella NR; Marzotti S; Lucidi P; Luzio S; Owens DR; Bolli GB; Fanelli CG
Diabetes Care; 2007 Oct; 30(10):2447-52. PubMed ID: 17623819
[TBL] [Abstract][Full Text] [Related]
4. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique.
Becker RH; Frick AD; Burger F; Scholtz H; Potgieter JH
Exp Clin Endocrinol Diabetes; 2005 May; 113(5):292-7. PubMed ID: 15926116
[TBL] [Abstract][Full Text] [Related]
6. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
Becker RH; Frick AD; Burger F; Potgieter JH; Scholtz H
Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
[TBL] [Abstract][Full Text] [Related]
7. Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects.
Becker RH; Frick AD; Teichert L; Nosek L; Heinemann L; Heise T; Rave K
Diabetes Obes Metab; 2008 Nov; 10(11):1105-13. PubMed ID: 18355326
[TBL] [Abstract][Full Text] [Related]
8. Glargine and regular human insulin similarly acutely enhance endothelium-dependent vasodilatation in normal subjects.
Westerbacka J; Bergholm R; Tiikkainen M; Yki-Järvinen H
Arterioscler Thromb Vasc Biol; 2004 Feb; 24(2):320-4. PubMed ID: 14656737
[TBL] [Abstract][Full Text] [Related]
9. Glargine and protamine zinc insulin have a longer duration of action and result in lower mean daily glucose concentrations than lente insulin in healthy cats.
Marshall RD; Rand JS; Morton JM
J Vet Pharmacol Ther; 2008 Jun; 31(3):205-12. PubMed ID: 18471141
[TBL] [Abstract][Full Text] [Related]
10. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
Dashora UK; Sibal L; Ashwell SG; Home PD
Diabet Med; 2007 Apr; 24(4):344-9. PubMed ID: 17298589
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus
Bhatia A; Tawade S; Mastim M; Kitabi EN; Gopalakrishnan M; Shah M; Yeshamaina S; Gobburu J; Sahib M; Thakur D; Prasanna Kumar KM
Acta Diabetol; 2018 May; 55(5):461-468. PubMed ID: 29453671
[TBL] [Abstract][Full Text] [Related]
12. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study.
Cernea S; Kidron M; Wohlgelernter J; Raz I
Clin Ther; 2005 Oct; 27(10):1562-70. PubMed ID: 16330292
[TBL] [Abstract][Full Text] [Related]
13. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.
Ashwell SG; Gebbie J; Home PD
Diabet Med; 2006 Aug; 23(8):879-86. PubMed ID: 16911626
[TBL] [Abstract][Full Text] [Related]
14. Dosing of insulin glargine in the treatment of type 2 diabetes.
Barnett A
Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
[TBL] [Abstract][Full Text] [Related]
15. Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles.
Mudaliar S; Mohideen P; Deutsch R; Ciaraldi TP; Armstrong D; Kim B; Sha X; Henry RR
Diabetes Care; 2002 Sep; 25(9):1597-602. PubMed ID: 12196433
[TBL] [Abstract][Full Text] [Related]
16. Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study.
Horvath K; Bock G; Regittnig W; Bodenlenz M; Wutte A; Plank J; Magnes C; Sinner F; Fürst-Recktenwald S; Theobald K; Pieber TR
Diabetes Obes Metab; 2008 Jun; 10(6):484-91. PubMed ID: 17764465
[TBL] [Abstract][Full Text] [Related]
17. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
[TBL] [Abstract][Full Text] [Related]
18. AIR insulin capsules of different dose strengths may be combined to yield equivalent pharmacokinetics and glucodynamics.
de la Peña A; Seger M; Rave K; Heinemann L; Silverman B; Muchmore DB
Diabetes Technol Ther; 2009 Sep; 11 Suppl 2():S75-80. PubMed ID: 19772452
[TBL] [Abstract][Full Text] [Related]
19. Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.
Sørensen LP; Brock B; Mengel A; Rungby J; Moller N; Nielsen S; Vølund A; Schmitz O
Diabet Med; 2010 Jul; 27(7):830-7. PubMed ID: 20636965
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique.
Scholtz HE; Pretorius SG; Wessels DH; Becker RH
Diabetologia; 2005 Oct; 48(10):1988-95. PubMed ID: 16160867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
